Zoledronic Acid Administration in Acute Spinal Cord Injury

Completed · Phase 4

Conditions studied: Disuse Osteoporosis

In brief

In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA). Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI, as evidenced by serial densitometry determinations (DXA).

Key facts

Study ID
NCT02042872
Run by
James J. Peters Veterans Affairs Medical Center
People needed
21
Starts
2006-05-01
Expected to finish
2012-07-01
Last updated by the study team
2018-03-14

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.